Flputnam Investment Management Co. Takes $1.52 Million Position in Becton, Dickinson and Company $BDX

Key Points

• Flputnam Investment Management acquired 10,080 shares of Becton, Dickinson and Company worth approximately $1.52 million in the second quarter. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly revenue of $4.98 billion and EPS of $3.23, exceeding analyst expectations, while revenue increased 5.4% year over year. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• Analyst sentiment is mixed, with a consensus rating of Hold and an average price target of $185.67; BDX recently traded at $182.39. The company declared a quarterly dividend of $1.05, equivalent to a 2.3% annualized yield.

Flputnam Investment Management Co. purchased a new position in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,080 shares of the medical instruments supplier's stock, valued at approximately $1,525,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Global Retirement Partners LLC bought a new stake in Becton, Dickinson and Company in the second quarter valued at approximately $1,178,000. 1ST Source Bank acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at $218,000. Bank of New York Mellon Corp bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $247,372,000. Focus Partners Advisor Solutions LLC acquired a new stake in Becton, Dickinson and Company during the 2nd quarter worth $200,000. Finally, State of Wyoming bought a new position in Becton, Dickinson and Company during the second quarter worth about $370,000. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Down 0.6%

BDX stock opened at $182.39 on Tuesday. The company has a market cap of $50.26 billion, a price-to-earnings ratio of 54.94, a P/E/G ratio of 12.93 and a beta of 0.19. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The business has a 50 day moving average price of $158.48 and a two-hundred day moving average price of $161.26. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the prior year, the firm earned $3.68 EPS. Becton, Dickinson and Company's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is currently 126.51%.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 1,100 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 11,779 shares of company stock worth $1,974,669 in the last 90 days. Company insiders own 0.40% of the company's stock.

Wall Street Analyst Weigh In

BDX has been the subject of a number of research analyst reports. Jefferies Financial Group reissued a "buy" rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Citigroup reiterated a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday. UBS Group began coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a "buy" rating and a $190.00 target price for the company. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a report on Thursday, August 13th. Finally, Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source